Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
10.04
+0.48 (5.02%)
At close: Jul 2, 2026, 4:00 PM EDT
9.85
-0.19 (-1.89%)
After-hours: Jul 2, 2026, 5:09 PM EDT
Vir Biotechnology Revenue
Vir Biotechnology had revenue of $-29.00K in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $65.50M, up 213.96% year-over-year. In the year 2025, Vir Biotechnology had annual revenue of $68.56M, down -7.61%.
Revenue (ttm)
$65.50M
Revenue Growth
+213.96%
P/S Ratio
25.85
Revenue / Employee
$178,460
Employees
367
Market Cap
1.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 68.56M | -5.65M | -7.61% |
| Dec 31, 2024 | 74.21M | -11.98M | -13.90% |
| Dec 31, 2023 | 86.18M | -1.53B | -94.67% |
| Dec 31, 2022 | 1.62B | 520.38M | 47.51% |
| Dec 31, 2021 | 1.10B | 1.02B | 1,334.40% |
| Dec 31, 2020 | 76.37M | 68.28M | 843.86% |
| Dec 31, 2019 | 8.09M | -2.58M | -24.16% |
| Dec 31, 2018 | 10.67M | 7.96M | 293.94% |
| Dec 31, 2017 | 2.71M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.71B |
| Novavax | 596.34M |
| Innoviva | 420.69M |
| Immunocore Holdings | 412.81M |
| Ascentage Pharma Group International | 82.08M |
| Maze Therapeutics | 20.00M |
| Zenas BioPharma | 10.00M |
| Aktis Oncology | 8.28M |
VIR News
- 22 days ago - Vir Biotechnology price target raised to $27 from $23 at Morgan Stanley - TheFly
- 23 days ago - Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors - Business Wire
- 5 weeks ago - Vir Biotechnology Transcript: AGM 2026 - Transcripts
- 6 weeks ago - Vir Biotechnology to present complete week 96 data from Phase 2 SOLSTICE trial - TheFly
- 6 weeks ago - Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 - Business Wire
- 7 weeks ago - Vir Biotechnology Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Vir Biotechnology price target lowered to $23 from $24 at Morgan Stanley - TheFly
- 2 months ago - Vir Biotechnology reports Q1 EPS (85c) vs. (88c) last year - TheFly